02 Dec 09
The phrase Halcyon days is a literary commonplace in the English language English language and culture, signifying ideals of prosperity, bonhomie, joy, liberation, or tranquility. I can testify to experiencing all these sentiments having worked in Clinical R&D for nearing 30 years. I'm not so certain we'll ever return to the same again though.
Ann Maloney BSc FICR
26 Nov 09
I recently surveyed a range of pharmaceutical HR managers and recruiters to find out what they consider to be the worst errors you can make on your CV when applying for a pharma job. The results were quite surprising and funny at times, so I have compiled the following 10 point checklist to help you with your CV.
17 Nov 09
We're having a fascinating day at the Financial Times Global Pharmaceutical and Biotechnology conference on London.
17 Nov 09
The craving for cheap drugs has never been greater. For those patients and policymakers in developing countries, the existence of parallel imports is less a concern than a blessing. Yet for pharmaceutical companies themselves, there is the concern that an increasing trade in parallel imports would severely damage research-intensive activities and ultimately slow down the development of the very same drugs that are being traded in ‘grey’ markets today.
27 Oct 09
Whatever happened to the days of donning your best suit and tie and going out and looking for a job? Knocking on doors and meeting prospective employers, dazzling them with your wit, intelligence and enthusiasm. Unfortunately that is not possible in today’s society.
Trevor Abbott - PharmiWeb Field Reporter
13 Oct 09
Ever since the H1N1 virus first came onto the world map in April, ‘Where’s the vaccine?’ has been the cardinal question on everybody’s lips. As world governments scrambled to control the outbreak, supranational bodies such as the World Health Organization (WHO) threw themselves at the task of producing weekly updates for a virus which we originally knew very little about.
30 Sep 09
It is frightening because no one knows what's causing it, said a 28-year old law student who went to the St. Mark's Clinic in Greenwich Village last week complaining of swollen glands, thought to be one early symptom of the disease. Every week a new theory comes out about how you're going to spread it. - The New York Times , August 8th 1982.
28 Sep 09
A meta-analysis of the CRYSTAL and OPUS studies involving 845 patients with metastatic colorectal cancer (mCRC) tumours displaying the wild-type KRAS gene, has revealed first-line treatment with Erbitux (cetuximab) and FOLFOX4 or FOLFIRI chemotherapy significantly extends overall survival.
Olwen Glynn Owen
25 Sep 09
With the pharmaceutical industry heading into the well documented “expiry cliff” competition is rife. Quicker more cost effective methods of manufacturing must be found for big pharma to remain competitive and a clearer means of communication such as that seen at the NG Pharma Summit is clearly vital.
NG Online News
17 Sep 09
Hardly a day goes by without a new report, today AT Kearney, last week Roland Berger and before them IMS and PWC warning of a gloomy future for pharmaceutical companies and saying that they must change their ways.
Paul Dixey, Managing Partner, BlueLight Partners
16 Sep 09
More than half of schizophrenia patients are expected to relapse within two years if untreated and 4 out of 5 within five years, according to experts. Antipsychotics can reduce the relapse rate so long as patients continue on treatment. However, adherence is notoriously poor. A new antippsychotic – asenapine – shows promise of being effective and better tolerated.
Olwen Glynn Owen
11 Aug 09
As Capitol Hill readies itself for the August Recess, and as President Barack Obama demands that a bill reach his desk in the Oval Office by October, healthcare reform still finds itself in more-or-less the same quagmire as it did in 1993. We take a look at the chances of comprehensive reform this year and tackle the nitty-gritty of one of the most complex and polarising issues of Washington politics today.
15 Jul 09
With increased investment in R&D largely failing to fill drug development pipelines, the pharma industry is looking to get more bang for its R&D buck by generating some return out of failed drug candidates and extra return out of others. Drug re-positioning has become a key strategy for pharmaceutical groups, and according to Datamonitor, this approach is set to become more frequently employed.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.